Rigel Pharmaceuticals Inc(RIGL) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trials for warm autoimmune hemolytic anemia; R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trials for autoimmune and inflammatory diseases; and R552, a receptor-interacting protein kinase Inhibitor that is in phase I clinical trials for autoimmune and inflammatory diseases. The company has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. Tavalisse. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Current Price

$3.79

RSI

68.616

Beta:

1.5091

March 31, 2021
8.9M
-20M

43.789 %
70.265 %
94.280 %
86.284 %

$112,611,000
$64,163,000
$44,509,000
$4,484,000
$20,383,000
$28,895,000
75.508 %
44.157 %
892.618 %
-78.001 %
-29.458 %

$-33,844,000
$-88,494,000
$-78,880,000
$-164,692,000
$-95,116,000
$-51,464,000
61.756 %
-12.188 %
52.105 %
-73.149 %
-84.820 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.